A2A Pharmaceuticals has designed new drug candidates for cancers like Leukemia and other life threatening diseases. A2A’s technology platform optimizes the efficacy of such options while minimizing toxicity much faster and more precisely than competitors. We build and evaluate small molecule libraries that consist of thousands to millions of members until we obtain candidates with optimal properties and matches.